CA2102120A1 - Use of a 1,3-oxathlolan derivative for the treatment of hepatitis b infection - Google Patents

Use of a 1,3-oxathlolan derivative for the treatment of hepatitis b infection

Info

Publication number
CA2102120A1
CA2102120A1 CA002102120A CA2102120A CA2102120A1 CA 2102120 A1 CA2102120 A1 CA 2102120A1 CA 002102120 A CA002102120 A CA 002102120A CA 2102120 A CA2102120 A CA 2102120A CA 2102120 A1 CA2102120 A1 CA 2102120A1
Authority
CA
Canada
Prior art keywords
compound
formula
hepatitis
treatment
oxathiolan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002102120A
Other languages
English (en)
French (fr)
Inventor
Phillip Allen Furman Jr.
George Robert Painter Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2102120A1 publication Critical patent/CA2102120A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002102120A 1991-05-02 1992-05-01 Use of a 1,3-oxathlolan derivative for the treatment of hepatitis b infection Abandoned CA2102120A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919109506A GB9109506D0 (en) 1991-05-02 1991-05-02 Therapeutic nucleosides
GB9109506.7 1991-05-02

Publications (1)

Publication Number Publication Date
CA2102120A1 true CA2102120A1 (en) 1992-11-03

Family

ID=10694346

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002102120A Abandoned CA2102120A1 (en) 1991-05-02 1992-05-01 Use of a 1,3-oxathlolan derivative for the treatment of hepatitis b infection

Country Status (14)

Country Link
EP (1) EP0583274A1 (pt)
JP (1) JPH06506929A (pt)
AU (1) AU1662092A (pt)
CA (1) CA2102120A1 (pt)
GB (1) GB9109506D0 (pt)
IE (1) IE921363A1 (pt)
IL (1) IL101757A0 (pt)
MX (1) MX9203214A (pt)
MY (1) MY137298A (pt)
PT (1) PT100435B (pt)
RU (1) RU2104700C1 (pt)
UA (1) UA37251C2 (pt)
WO (1) WO1992019246A1 (pt)
ZA (1) ZA923185B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
MXPA01006425A (es) 1998-12-23 2002-06-04 Iaf Biochem Int Analogos de nucleosido antivirales.
AR049297A1 (es) * 2004-06-08 2006-07-12 Vertex Pharma Una composicion farmaceutica y dispersiones solidas de vx-950 (inhibidor de la proteasa de hcv ns3/4a) y proceso de obtencion
RU2331420C2 (ru) * 2005-12-08 2008-08-20 Роберт Шалвович Бибилашвили Противовирусное средство (варианты) и способ лечения на его основе

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5159067A (en) * 1987-01-28 1992-10-27 University Of Georgia Research Foundation Inc. 5'-Diphosphohexose nucleoside pharmaceutical compositions
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
EP0472595A4 (en) * 1989-05-15 1992-07-08 Us Commerce Method of treatment of hepatitis
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds

Also Published As

Publication number Publication date
IE921363A1 (en) 1992-11-04
JPH06506929A (ja) 1994-08-04
GB9109506D0 (en) 1991-06-26
IL101757A0 (en) 1992-12-30
PT100435A (pt) 1993-09-30
RU2104700C1 (ru) 1998-02-20
PT100435B (pt) 1999-08-31
MX9203214A (es) 1992-07-01
EP0583274A1 (en) 1994-02-23
UA37251C2 (uk) 2001-05-15
MY137298A (en) 2009-01-30
ZA923185B (en) 1993-11-01
AU1662092A (en) 1992-12-21
WO1992019246A1 (en) 1992-11-12

Similar Documents

Publication Publication Date Title
EP0574487B1 (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b
IE84129B1 (en) Therapeutic nucleosides
CA2102120A1 (en) Use of a 1,3-oxathlolan derivative for the treatment of hepatitis b infection
US20080187580A1 (en) Therapeutic nucleosides
CA2044125A1 (en) Anti-hbv pyrimidine nucleoside
EP0620734A1 (en) Therapeutic nucleosides
NZ264990A (en) Use of 1-(2-(hydroxymethyl))-1,3-oxathiolan-5-yl)cytosine derivatives to prepare medicaments and methods of treatment of hepatitas b virus infections
CA2439322A1 (en) Therapeutic nucleosides
IE85820B1 (en) Use of 5 - fluoro -2'deoxy-3' thiacytidine for the treatment of hepatitis B

Legal Events

Date Code Title Description
FZDE Discontinued